CoChat
Sign Up
Cited by 113

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo

Villard, Elise F., Thedrez, Aurélie, Blankenstein, Jorg, Croyal, Mikaël, Tran, Thi-Thu-Trang, Poirier, Bruno, Le Bail, Jean-Christophe, Illiano, Stéphane, Nobécourt, Estelle, Krempf, Michel, Blom, Dirk J., Marais, A. David, Janiak, Philip, Muslin, Anthony J., Guillot, Etienne, Lambert, Gilles·2016·JACC: Basic to Translational Science
DOI 10.1016/j.jacbts.2016.06.006PMC PMC5753417
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacbts.2016.06.006

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 20

  1. Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1489, 10.1056/NEJMoa1501031 · DOI · Paper page
  2. Ballantyne, 2015, Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia, Am J Cardiol, 115, 1212, 10.1016/j.amjcard.2015.02.006 · DOI
  3. Marais, 2015, PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels, Pharmacol Ther, 145, 58, 10.1016/j.pharmthera.2014.07.004 · DOI
  4. Lambert, 2014, Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab, J Am Coll Cardiol, 64, 2299, 10.1016/j.jacc.2014.07.995 · DOI
  5. Raal, 2014, Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials, J Am Coll Cardiol, 63, 1278
  6. Lamon-Fava, 2014, Lipoprotein(a) metabolism, Curr Opin Lipidol, 25, 189, 10.1097/MOL.0000000000000070 · DOI
  7. Alonso, 2014, Lipoprotein(a) levels in hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation, J Am Coll Cardiol, 63, 1982, 10.1016/j.jacc.2014.01.063 · DOI · Paper page
  8. Erqou, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063 · DOI · Paper page
  9. Rader, 1994, The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate, J Clin Invest, 93, 2758, 10.1172/JCI117292 · DOI
  10. Tsimikas, 2012, Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies, J Am Coll Cardiol, 60, 716, 10.1016/j.jacc.2012.04.038 · DOI
  11. Romagnuolo, 2015, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor, J Biol Chem, 290, 11649, 10.1074/jbc.M114.611988 · DOI · Paper page
  12. Lambert, 2014, Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects, J Am Coll Cardiol, 63, 2365, 10.1016/j.jacc.2014.02.538 · DOI
  13. Croyal, 2015, Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients, Arterioscler Thromb Vasc Biol, 35, 2042, 10.1161/ATVBAHA.115.305835 · DOI
  14. Etxebarria, 2015, Functional characterization and classification of frequent low-density lipoprotein receptor variants, Hum Mutat, 36, 129, 10.1002/humu.22721 · DOI · Paper page
  15. Reblin, 1997, Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein, J Lipid Res, 38, 2103, 10.1016/S0022-2275(20)37140-6 · DOI · Paper page
  16. Niemeier, 1999, Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro, Arterioscler Thromb Vasc Biol, 19, 552, 10.1161/01.ATV.19.3.552 · DOI
  17. Stein, 2013, Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia, Circulation, 128, 2113, 10.1161/CIRCULATIONAHA.113.004678 · DOI · Paper page
  18. Rader, 1995, The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans, J Clin Invest, 95, 1403, 10.1172/JCI117794 · DOI · Paper page
  19. Tavori, 2015, On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects, Atherosclerosis, 238, 264, 10.1016/j.atherosclerosis.2014.12.017 · DOI · Paper page
  20. Tavori, 2013, Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis, Circ Res, 113, 1290, 10.1161/CIRCRESAHA.113.302655 · DOI

Cited by

Sorted by citations

Metadata

Authors
Villard, E. F., Thedrez, A., Blankenstein, J., Croyal, M., Tran, T.-T.-T., Poirier, B., Le Bail, J.-C., Illiano, S., Nobécourt, E., Krempf, M., Blom, D. J., Marais, A. D., Janiak, P., Muslin, A. J., Guillot, E., & Lambert, G.
Venue
JACC: Basic to Translational Science
Publisher
Elsevier BV
Published
2016-10
Volume
1
Issue
6
Pages
419-427
ISSN
2452-302X
DOI
10.1016/j.jacbts.2016.06.006
PMC
PMC5753417
Cited by
113
References
3
Language
en
Licence
Funders
  • Amgen
  • Pfizer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review